SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is trending sharply lower as a broad market sell-off gains momentum, with traders expressing pervasive bearish sentiment and questioning market stability. This downturn is largely attributed to recent weak economic data, like existing home sales, and investor positioning ahead of tomorrow's critical CPI report.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is actively discussed ahead of its earnings report, with community sentiment deeply divided between fears of further decline following Robinhood's crypto revenue miss and those who see current lows as an oversold buying opportunity; ongoing debates around CEO Brian Armstrong's stance on the "Clarity Act" add further complexity to the conversation.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is seeing intense selling pressure after its latest earnings report revealed a revenue miss, primarily from a steep drop in crypto trading, igniting a fierce community debate about whether the stock is oversold or destined for deeper declines amidst concerns of market manipulation and its strong correlation with the volatile crypto market.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is facing significant investor unease and a sharp sell-off, driven by the intense antitrust scrutiny surrounding its contentious Warner Bros. Discovery acquisition and a competing all-cash bid from Paramount, prompting widespread community debate over management's strategy and the company's future valuation.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is trending amid a significant multi-day price decline that accelerated after earnings, where its substantial projected capital expenditure for AWS, AI, and logistics raised investor concerns about near-term profitability. While many in the community debate the stock's valuation and underperformance, others view the current pullback as a prime buying opportunity given Amazon's long-term business strength and strategic investments.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is trending after reporting strong earnings and an optimistic outlook, yet its stock experienced a notable sell-off, prompting community discussion about potential market manipulation and broader weakness within the software sector. Many investors are viewing the sharp decline as an unjustified overreaction and a buying opportunity, while others express concerns about valuation and the impact of AI.

Canadian Imperial Bank of Commerce is a financial institution, which engages in the provision of banking and wealth management services. It operates through the following segments: Canadian Personal and Business Banking, Canadian Commercial Banking and Wealth Management, U.S. Commercial Banking and Wealth Management, Capital Markets and Direct Financial Services, and Corporate and Other. The Canadian Personal and Business Banking segment provides financial advice, services, and solutions. The Canadian Commercial Banking and Wealth Management segment caters to middle-market companies, entrepreneurs, high-net-worth individuals, families, and asset management services to institutional investors. The U.S. Commercial Banking and Wealth Management segment includes provision of solution and services across the U.S., focusing on middle-market and mid-corporate companies, entrepreneurs, high-net-worth individuals, families, and operating personal and small business banking services in four U.S. markets. Capital Markets and Direct Financial Services segment consists of integrated global markets products and services, investment and corporate banking, and research. The Corporate and Other segment refers to the functional groups such as technology, infrastructure, innovation, risk management, people, culture and brand, finance and enterprise strategy, and other support groups. The company was founded on June 1, 1961 and is headquartered in Toronto, Canada.

Canadian Imperial Bank Of Commerce

Canadian Imperial Bank of Commerce is trending as it reaches new highs, fueled by consistently strong earnings reports and dividend increases, amidst a broader rally in the Canadian banking sector. Despite this positive momentum, community discussions also focus on an ongoing multi-million dollar lawsuit alleging stock manipulation against the bank.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is experiencing intense volatility, with recent weaker economic data and persistent selling pressure on major tech names fueling bearish sentiment and discussions of market manipulation. Despite calls for further downside, many traders anticipate or are actively looking for 'V-shape' reversals, creating a highly contested trading environment ahead of upcoming inflation data.

Fastly, Inc. provides real-time content delivery network services. It offers edge compute, edge delivery, edge security, edge applications like load balancing and image optimization, video on demand, and managed edge delivery. The company was founded by Artur Bergman, Tyler McMullen, Simon Wistow, and Gil Penchina in March 2011 and is headquartered in San Francisco, CA.

Fastly Inc - Ordinary Shares - Class A

Fastly Inc

Fastly is trending due to stellar quarterly results, strong guidance, and its emerging narrative as a critical player in the 'Edge of AI' and inference infrastructure. This impressive performance and high short interest are fueling intense discussion about a potential short squeeze, leading many in the community to anticipate substantial future growth.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 and is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance is trending due to its revised all-cash offer for Warner Bros. Discovery, which includes a ticking fee and covers Netflix's breakup costs, as investors weigh its clearer regulatory path against Netflix's increasing DOJ scrutiny. Community sentiment is divided, with some seeing value in PSKY's strategic moves like the successful UFC event, while others remain frustrated by the stock's persistent decline amidst the ongoing merger drama.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Novavax (NVAX) Rises As Market Takes a Dip: Key Facts

Novavax (NVAX) reached $8.97 at the closing of the latest trading day, reflecting a +2.51% change compared to its last close.

<ul class="summary-bullets"><li>The regulator said the Phase 3 study comparator did not reflect the “best-available standard of care,” though it raised no safety or efficacy concerns.</li><li>Moderna said the refusal conflicts with prior FDA guidance that allowed the comparator.</li><li>CEO Stephane Bancel will seek clarity through a requested Type A meeting.</li></ul><p>Shares of Moderna, Inc. (MRNA) fell about 9% in after-hours trading on Tuesday after the company said U.S. regulators declined to accept its application for review of its experimental seasonal influenza vaccine, marking another regulatory setback for the vaccine maker.</p><p>In the regular session,&nbsp;<a href="https://stocktwits.com/symbol/MRNA">MRNA stock</a> rose 0.1% to $41.99. The regulatory setback also lifted shares of rival Novavax, which is developing a protein-based seasonal influenza vaccine candidate, with the stock rising more than 1% in after-hours trading.</p><h2 class="st-heading-2"><strong>FDA Rejects Moderna Flu Vaccine Filing</strong></h2><p>Moderna said the U.S. Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research (CBER) issued a refusal-to-file letter for the biologics license application (BLA) of its investigational flu vaccine, mRNA-1010, and will not initiate a review, despite the company using a priority review voucher.</p><p>The letter said the application lacked an “adequate and well-controlled” study using a comparator reflecting the “best-available standard of care,” and did not raise any safety or efficacy concerns.</p><p>The BLA includes two positive Phase 3 studies enrolling 43,808 participants. One showed a stronger immune response and a favorable safety profile compared with a high-dose flu shot in adults aged 65 and older, while the other showed higher effectiveness than a standard-dose vaccine in adults aged 50 and older. Moderna said the FDA reviewed and cleared both trial designs before the studies began.</p><p>The decision was signed by Vinay Prasad, who is also known for halting broader access to Sarepta Therapeutics’ gene therapy Elevidys, drawing backlash over access to the only approved treatment for Duchenne muscular dystrophy.</p><h2 class="st-heading-2"><strong>Moderna Flags Inconsistency In FDA Feedback</strong></h2><p>Moderna said the refusal conflicted with earlier written guidance from the FDA’s CBER. In April 2024, regulators said using a licensed standard-dose influenza vaccine as the comparator would be acceptable, while recommending a high-dose or an adjuvanted vaccine for participants&nbsp;aged 65 and older. The company said no objections or clinical holds were raised after the Phase 3 protocol was submitted or before the trial began in September 2024.</p><p>After the Phase 3 study met all pre-specified endpoints, Moderna said it provided additional comparator analyses requested during an August 2025 pre-submission meeting, including data from a separate Phase 3 trial comparing a licensed high-dose flu vaccine with a comparator. Moderna said the FDA did not signal it would refuse to review the application.</p><p>CEO Stephane Bancel said the decision&nbsp;was based on no safety or efficacy issues and that the company would seek clarity on the path forward.</p><h2 class="st-heading-2"><strong>Moderna Seeks Type A FDA Meeting</strong></h2><p>Moderna said it has requested a Type A meeting with CBER. The company said mRNA-1010 has been accepted for review in the European Union, Canada and Australia, with additional country submissions planned for 2026. It expects the earliest potential approvals outside the U.S. in late 2026 or early 2027 and said the FDA decision will not affect its 2026 financial guidance.</p><h2 class="st-heading-2"><strong>Regulatory Backdrop Weighs On Vaccine Makers</strong></h2><p>The FDA decision adds to regulatory uncertainty facing vaccine manufacturers in the U.S. Last month, Bancel told&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2026-01-22/moderna-mrna-curbs-investment-in-vaccine-trials-due-to-us-backlash">Bloomberg</a> at the World Economic Forum in Davos that Moderna does not plan to invest in new late-stage vaccine trials without clearer access to the U.S. market, citing regulatory delays and reduced support for immunization programs.</p><p>In December, a leaked internal email from Prasad surfaced, asserting that COVID-19 vaccines were linked to at least 10 pediatric deaths, a claim experts said lacked supporting data. Moderna has been seeking to diversify beyond its COVID-19 vaccines and is focusing on personalized cancer vaccines, while also looking for external funding partners to advance certain late-stage vaccine programs.</p><h2 class="st-heading-2"><strong>How Did Stocktwits Users React?</strong></h2><p>On Stocktwits, retail sentiment for MRNA was ‘bearish’ amid ‘low’ message volume.</p><figure class="image"><img src="https://news.stocktwits-cdn.com/mrna_ss_png_b80d531229.webp" alt="mrna ss.png" width="969" height="143"><figcaption>MRNA sentiment and message volume as of February 10 | Source: Stocktwits</figcaption></figure><p>One bearish user said, “So glad I sold at $49 this time round. This is going to struggle to stay solvent soon.”</p><p><stembedurl>https://stocktwits.com/TopazFrenzy/message/644621591</stembedurl></p><p>Another user called the company a “Great short!” and expects the stock to trade in the range of $20-$28.</p><p><stembedurl>https://stocktwits.com/Tradebub/message/644623819</stembedurl></p><p>MRNA stock has risen 32% over the past 12 months.</p><p>See Also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/mrna-vs-nvax-which-vaccine-stock-is-wall-street-more-bullish-on-right-now/cmUzkZbR4QI">MRNA Vs NVAX: Which Vaccine Stock Is Wall Street More Bullish On Right Now?</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, Moderna’s logo is displayed on a smartphone with an economic stock exchange index graph in the background. (Photo Illustration by Budrul Chukrut/SOPA Images/LightRocket via Getty Images)

Why Did Moderna Stock Tumble Nearly 10% After Hours Today?

The FDA’s CBER issued a refusal-to-file letter for Moderna’s flu vaccine mRNA-1010.

Equity

Allianz Asset Management GmbH Acquires 872,987 Shares of Novavax, Inc. $NVAX

Allianz Asset Management GmbH lifted its holdings in Novavax, Inc. (NASDAQ:NVAX - Free Report) by 162.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities...

Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know  

Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Why Novavax (NVAX) Dipped More Than Broader Market Today

Novavax (NVAX) concluded the recent trading session at $8.37, signifying a -3.68% move from its prior day's close.

Novavax (NASDAQ:NVAX) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen cut Novavax from a "hold" rating to a "sell" rating in a research report on Saturday...

Here's Why Novavax (NVAX) Fell More Than Broader Market

In the latest trading session, Novavax (NVAX) closed at $9.22, marking a -6.07% move from the previous day.

Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It

Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Novavax (NVAX) Stock Dips While Market Gains: Key Facts

In the latest trading session, Novavax (NVAX) closed at $9.71, marking a -1.97% move from the previous day.

<ul class="summary-bullets"><li>Analysts see greater upside in Novavax, while Moderna carries a ‘Hold’ rating despite stronger gains over the past year.</li><li>Moderna was in focus after updated cancer vaccine data, while Novavax drew attention following its Pfizer licensing deal.</li><li>Retail sentiment on Stocktwits was 'extremely bullish' for both stocks, with message activity sharply higher over the past year.</li></ul><p>Wall Street is&nbsp;a bit&nbsp;split on Moderna and Novavax, with analysts favoring upside in one name even as the other has outperformed over the past year.</p><h2 class="st-heading-2"><strong>Analysts Favor Novavax Over Moderna</strong></h2><p>Koyfin data shows analysts assigning greater upside to Novavax than Moderna based on consensus price targets.</p><p>Moderna shares were last trading around $49.81 on Wednesday, but Wall Street’s expectations remain cautious. The stock’s average 12-month price target is $37.40, a 25% downside from current levels. Among the 24 analysts covering the company, the overall view sits at ‘Hold’, with two ‘Strong Buy’, two ‘Buy’, 17 ‘Hold’, one ‘Sell’, and two ‘Strong Sell’ ratings, giving Moderna an overall ‘Hold’ rating.</p><p>Meanwhile, Novavax last closed at $9.9 on Wednesday, and analysts see room for gains. The stock’s average 12-month price target of $12.89 points to a 30% upside&nbsp;from current levels. Among the nine analysts tracking the company, five rate it ‘Buy’, one ‘Hold’, one ‘Sell’, and two ‘Strong Sell’, giving Novavax an overall ‘Buy’ rating.</p><p>Over the past 12 months,&nbsp;<a href="https://stocktwits.com/symbol/NVAX">Novavax shares</a>&nbsp;have been up about 12%, while&nbsp;<a href="https://stocktwits.com/symbol/MRNA">Moderna</a> has gained roughly 39%.</p><h2 class="st-heading-2"><strong>Moderna Faces Analyst Caution</strong></h2><p>On Tuesday,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/moderna-stock-still-worth-37-less-after-cancer-vaccine-data-bof-a-s-new-price-target-keeps-retail-traders-cautious/cmUDauIR4OV">Bank of America Securities raised its price target to $27 from $24</a> while keeping an ‘Underperform’ rating, implying a 37% downside based on the stock’s prior close near $43.</p><p>The update followed the release of&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/moderna-shares-rise-on-five-year-follow-up-takeaways-for-skin-cancer-vaccine/cmUuq4QR4OT">five-year follow-up data</a> for Moderna’s personalized cancer vaccine Intismeran Autogene, developed with Merck and used alongside Keytruda in patients with high-risk melanoma. Moderna and Merck said patients receiving the combination showed a 49% lower risk of cancer recurrence or death compared with Keytruda alone.&nbsp;</p><p>Earlier this month, UBS downgraded the stock to ‘Neutral’ from ‘Buy’ and cut its price target to $34 from $40, implying about 32% downside from its last close.&nbsp;</p><p>Moderna expects regulatory approvals this year for a standalone flu vaccine and a COVID-19/flu combination shot, though not in time for the 2026 respiratory season, with a potential boost in 2027. The company also expects key trial data in 2026, including late-stage norovirus results and mid-stage melanoma data.&nbsp;</p><h2 class="st-heading-2"><strong>Novavax In Focus</strong></h2><p>This week, Novavax&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-nvax-stock-rising-premarket-pfizer-matrix-m-deal/cmUumrjR4aq">signed a non-exclusive licensing deal with Pfizer</a> for up to two disease areas using its Matrix-M adjuvant. The deal includes a $30 million upfront payment, as well as the possibility of up to $500 million in development and sales milestones, and tiered royalties in the high mid-single-digit range.&nbsp;</p><p>That deal followed Novavax handing over U.S. and European rights to its Covid-19 vaccine candidate Nuvaxovid to Sanofi in November for undisclosed upfront payments and possible milestones. The deal also opens the door&nbsp;to future royalties. Novavax also has deals with Takeda and the Serum Institute of India.</p><p>Novavax has pushed its profitability target to 2028 as Covid-19 vaccine demand remains under pressure, while activist investor Shah Capital, which holds about 8.3%, has&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novavax-stock-faces-retail-backlash-as-shah-capital-warns-of-proxy-fight-and-presses-for-a-sale/cLPBFk7REdt">urged the board to review strategic alternatives</a>, including a potential sale.</p><h2 class="st-heading-2"><strong>Regulatory Backdrop</strong></h2><p>Uncertainty over regulatory approval also looms for both companies. Shares of Moderna and Novavax fell in December after an FDA memo to staff, which did not name a manufacturer, warned of safety problems with vaccines that could lead to tougher approval standards.</p><p>Novavax’s COVID-19 vaccine has full FDA approval with age- and risk-level-based restrictions, while Moderna's COVID-19 vaccines have full licensure across broader age groups.</p><h2 class="st-heading-2"><strong>How Did Stocktwits Users React?</strong></h2><p>On Stocktwits, retail sentiment toward Moderna was ‘extremely bullish’ amid ‘extremely high’ message volume, with watchers up 3% and message activity more than doubling over the past 12 months.</p><figure class="image"><img src="https://news.stocktwits-cdn.com/mrna_ss_png_124327497e.webp" alt="mrna ss.png" width="971" height="142"><figcaption>MRNA sentiment and message volume as of January 21 | Source: Stocktwits</figcaption></figure><p>On the other hand, retail sentiment toward Novavax was ‘extremely bullish’ amid ‘extremely high’ message volume, with watchers up 5% and message activity surging more than 600% over the past 12 months.</p><figure class="image"><img src="https://news.stocktwits-cdn.com/nvax_ss_png_ec285c2653.webp" alt="nvax ss.png" width="969" height="138"><figcaption>NVAX sentiment and message volume as of January 21 | Source: Stocktwits</figcaption></figure><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

 In this photo illustration vials of vaccines for coronavirus (COVID-19). Vaccines from left to right, Moderna, Bimervax, Comirnaty and Pfizer BioNTech. (Photo Illustration by Marcos del Mazo/LightRocket via Getty Images)

MRNA Vs NVAX: Which Vaccine Stock Is Wall Street More Bullish On Right Now?

Regulatory uncertainty remains a common factor for both companies following an FDA memo that raised concerns about vaccine safety.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

3%+ above current levels

Up 0–3%

Flat to down 3%

Down 3%+

With earnings season underway and rate-cut expectations shifting, the next move in the S&P 500 could set the tone for 2026. Are bulls still in control, or is volatility about to pick up? Cast your vote.

Stocktwits

Stocktwits Polls

Novavax Inc

The FDA's refusal to review Moderna's mRNA flu vaccine creates a strategic advantage for Novavax's protein-based platform, especially for its combination shot.

Bank of America, known for prior 'sell' ratings, has disclosed a significant 5.10% stake, fueling speculation of price manipulation for institutional accumulation.

Traders are actively discussing high short interest and bullish technicals, anticipating a significant short squeeze as buying pressure builds.

Renewed speculation centers on potential acquisitions or lucrative partnerships from major pharmaceutical companies for Matrix-M and the combined vaccine pipeline.

NVAX
Novavax Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest NVAX News

NVAXNovavax Inc